ProPublica Reporting on Healthcare Issues
by Charles Ornstein
ProPublica, April 1, 4 p.m.
Nearly every
large drug maker based in the United
States had at least one academic medical
center official on its board, raising questions about their independence.
by Charles Ornstein
ProPublica, March 28, 11:57 a.m.
With more
data on relationships between doctors and drug companies soon to be released,
here are some ways journalists can use this information.
by Charles
Ornstein and Ryann Grochowski Jones
ProPublica, March 25, Midnight
Research has
been seen as less objectionable than other forms of interactions with drug
companies, but 10 percent of researchers have multiple ties among the nine
companies ProPublica analyzed. That raises questions
about doctors’ impartiality.
by Eric Sagara
ProPublica, March 11, 3:24 p.m.
Pharmaceutical
company payments to health care professionals dropped between 2011 and 2012
among most of the companies and categories ProPublica
tracks, driven in part by increased transparency as well as blockbuster drugs
losing patent protection. Research payments, however, have increased among th
by Charles
Ornstein, Eric Sagara and Ryann Grochowski Jones
ProPublica, March 3, 10:50 p.m.
As
transparency increases and blockbuster drugs lose patent protection, drug
companies have dramatically scaled back payments to doctors for promotional
talks. This fall, all drug and medical device companies will be required to
report payments to doctors.
by Charles Ornstein
ProPublica, March 3, 10:50 p.m.
Drugmaker Cephalon had been
required to post its payments to doctors online as part of a lawsuit
settlement. After its agreement expired, it removed them from its website.
by Charles Ornstein
ProPublica, Dec. 17, 2013, 10:31 a.m.
The
sixth-largest drug maker already had begun cutting back on paid speaking, ProPublica’s Dollars for Docs database shows.
by Theodoric Meyer
ProPublica, May 3, 2013, 3:01 p.m.
The drug
maker denies wrongdoing, but the Justice Department and a whistleblower say
Novartis used cash and meals to get doctors to prescribe its drugs.
by Jeremy B. Merrill
ProPublica, March 25, 2013, 11:24 a.m.
We updated
Dollars for Docs last week. Why is updating it so difficult?
by Blair Hickman
ProPublica, March 18, 2013, 6:14 p.m.
Our database
drugmaker payments to docs now
includes more than $2 billion to hundreds of thousands of physicians.
by Amanda Zamora
ProPublica, March 11, 2013, 11:51 a.m.
Has your
doctor received drug company money? Search ProPublica's
Dollars for Docs database.
by Tracy Weber
and Charles
Ornstein
ProPublica, March 11, 2013, 11 a.m.
New data
show drugmakers’ payments to hundreds of thousands of
doctors, and some have made well over $500,000.
by Charles
Ornstein, Tracy Weber
and Dan Nguyen
ProPublica, March 11, 2013, 11 a.m.
Details
behind our drug company money database.
Find More Excellent Reporting on Healthcare by ProPublica
at
by Nicholas Kusnetz
ProPublica, March 11, 2013, 11 a.m.
Drug
companies have long kept secret details of the payments they make to doctors
and other health professionals for promoting their drugs. Such payments aren't
necessarily wrong, but they can raise ethical issues
by Blair Hickman
ProPublica, March 11, 2013, 11 a.m.
Help inform
our ongoing reporting into the relationship between drug companies and medical
professionals.
by Charles
Ornstein and Tracy Weber
ProPublica, Feb. 1, 2013, 5:25 p.m.
After a long
delay, the U.S. Centers for Medicare and Medicaid Services published final
rules for the Physician Payments Sunshine Act, which would bring transparency
to financial relationships between physicians and industry.
by Marshall Allen
ProPublica, May 30, 2012, 6:56 a.m.
Charlie
Ornstein and Tracy Weber talk about the money docs get from drug companies, and why it matters.
by Charles
Ornstein and Tracy Weber
ProPublica, May 8, 2012, 8:57 p.m.
Sens. Baucus
and Grassley demand evidence of financial support from the drug industry to
nonprofit groups that advocate use of opioid
painkillers, including the newly defunct American Pain Foundation.
by Charles
Ornstein and Tracy Weber
ProPublica, Feb. 1, 2012, 11:03 a.m.
You can
still find some older Allergan payments in ProPublica's Dollars for Docs database, along with data
from 11 other drug companies.
by Charles
Ornstein and Tracy Weber
ProPublica, Jan. 24, 2012, 2:04 p.m.
Sen. Charles
Grassley, R-Iowa, wants to know why an Ohio doctor wrote 54 prescriptions per
weekday for the antipsychotic Abilify, while the
biggest prescriber of Seroquel wrote an average nine
prescriptions per hour.
by Tracy Weber
and Charles
Ornstein
ProPublica, Jan. 3, 2012, 2:55 p.m.
Continued
reporting on the influence of pharmaceutical money on medicine spurred tighter
rules at medical schools across the nation.
by Charles
Ornstein and Tracy Weber
ProPublica, Dec. 23, 2011, 2:15 p.m.
The annual
death toll from overdoses of painkillers has reached almost 15,000, prompting
the head of the CDC o term it an "epidemic." But the American Pain
Foundation continues to claim the risks are overblown. The
advocacy group's biggest supporter? The drug industry.
by Tracy Weber
and Charles
Ornstein
ProPublica, Dec. 23, 2011, 2:14 p.m.
American
Pain Foundation board members Scott Fishman and Perry Fine, both physicians,
have lectured and authored publications funded by makers of narcotic
painkillers. They say the support doesn’t bias them.
by Robin Respaut
ProPublica, Dec. 15, 2011, 3:22 p.m.
The agency
responsible for administering health care reform, the Centers for Medicare and
Medicaid Services, published proposed rules last night, well after its Oct. 1
deadline.
by Tracy Weber
and Charles
Ornstein
ProPublica, Nov. 17, 2011, 9:03 a.m.
Medicaid
programs have long had evidence that a few physicians prescribed risky drugs in
excess, but it wasn’t until Sen. Charles Grassley, R-Iowa, demanded to know the
top prescribers that states began to investigate.
by Marian Wang
ProPublica, Oct. 12, 2011, 11:46 a.m.
The Obama
administration has yet to draft rules on the disclosure of industry payments to
doctors, missing a deadline set out in last year's health-care law.
by Tracy Weber
and Charles
Ornstein
ProPublica, Sep. 16, 2011, 1:23 p.m.
At least 15
drug and medical-device companies have paid $6.5 billion since 2008 to settle
accusations of marketing fraud or kickbacks, but none of the more than 75
doctors named as participants were sanctioned.
by Charles
Ornstein and Tracy Weber
ProPublica, Sep. 8, 2011, 12:18 p.m.
Regional
newspapers that analyzed ProPublica's Dollars for
Docs data say drug company payments to physician speakers have declined in
their states, suggesting that new restrictions and publicity are making an
impact.
by Tracy Weber
and Charles
Ornstein
ProPublica, Sep. 7, 2011, 8 p.m.
ProPublica's newly updated Dollars for Docs database
offers a glimpse of what patients can expect in 2013, when all drug and
medical-device companies must report to the federal government what they pay
doctors to help market their products.
by Charles Ornstein
ProPublica, Sep. 7, 2011, 4:32 p.m.
Hundreds of
thousands of doctors have accepted free meals from pharmaceutical companies
that invite them to scientific or educational sessions. At least 20 physicians
accepted more than $2,000 worth of meals from one company last year, ProPublica's Dollars for Docs database shows.
by Charles
Ornstein, Tracy Weber
and Dan Nguyen
ProPublica, Sep. 7, 2011, 4:31 p.m.
An update of
ProPublica's Dollars for Docs database includes more
than $760 million in payments from 12 pharmaceutical companies to physicians and
other health-care providers for consulting, speaking, research and expenses.
by Charles
Ornstein and Tracy Weber
ProPublica, Sep. 7, 2011, 10:48 a.m.
As ProPublica gets ready to refresh its Dollars for Docs
database listing payments from drug companies to hundreds of thousands of
doctors, the Pharmaceutical Research and Manufacturers of America says paid
physician speakers play a critical role in improving patient care.
by Marian Wang
ProPublica, May 25, 2011, 1:30 p.m.
Two medical
groups recruited to lobby the Food and Drug Administration against generic
versions of a Sanofi-Aventis blood-thinner each
received millions from the manufacturer.
by Nicholas Kusnetz
ProPublica, May 20, 2011, 11:58 a.m.
Recommendations
made by two medical societies give at least the appearance of a conflict of
interest.
by Charles
Ornstein and Tracy Weber
ProPublica, May 19, 2011, 12:01 p.m.
Reacting to ProPublica's Dollars for Docs coverage, Stanford and other
schools discipline doctors, rewrite policies and
increase scrutiny of drug-industry ties.
by Charles Ornstein
ProPublica, May 13, 2011, 12:27 p.m.
The Society
for Cardiac Angiography and Interventions got more than half its income in 2009
from medical device and pharmaceutical makers. This week, a study in JAMA
questioned why more patients who received angioplasty and stents didn’t first
receive recommended medications.
by Charles Ornstein
ProPublica, May 9, 2011, 12:05 p.m.
Many
physicians attending the Heart Rhythm Society conference see little cause for
concern in the financial ties between medical societies and industry.
by Charles
Ornstein and Tracy Weber
ProPublica, May 5, 2011, 9:43 p.m.
by Charles
Ornstein and Tracy Weber
ProPublica, May 5, 2011, 8:48 p.m.
The Heart
Rhythm Society says the financial support it receives from drug and
medical-device makers plays no role in its advocacy for certain treatments, but
does not mention potential risks in its publications.
by Charles
Ornstein and Tracy Weber
ProPublica, May 5, 2011, 8:48 p.m.
Professional
groups like the Heart Rhythm Society write guidelines on treatments and the use
of medical devices, but researchers say their acceptance of sponsorships and
grants from drug and device makers poses a conflict of interest that many
patients never consider.
by Charles
Ornstein and Tracy Weber
ProPublica, May 5, 2011, 8:45 p.m.
The Heart Rhythm Society a set of questions about potential
conflicts of interest regarding the group’s acceptance of drug and device
industry marketing money.
by Dan Nguyen, ProPublica,
and Nicolas Rapp, Special to ProPublica May 5, 2011,
8:45 p.m.
The Heart
Rhythm Society’s annual conference is a marketing bonanza for drug companies
and medical device makers.
by Dan Nguyen, ProPublica,
and Nicolas Rapp, Special to ProPublica May 5, 2011,
8:43 p.m.
The Heart
Rhythm Society’s annual conference is a marketing bonanza for drug companies
and medical device makers. Use this interactive graphic to find out how
companies got their names seen.